Josip Skoko an ESR based in Stuttgart in Markus Rehm’s lab has published his work in BMC Cell Biology. The objective of his project was to identify reliable biomarkers to predict dasatinib responsiveness in melanoma and his results suggest that loss of p53 phosphorylation may be a potential candidate for a kinetic marker of dasatinib responsiveness in melanoma.

The paper is available here http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307246/

Great work Josip!